Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions.
Transfusion of platelet concentrates remains the first-line therapy for Glanzmann thrombasthenia in case of bleeding or preparation for surgery. However, development of antibodies to platelet glycoprotein (Gp) IIb/IIIa complex or human leukocyte antigens (HLA) is frequent and the main cause of platelet refractoriness. Recombinant activated factor VII (rFVIIa) is a potent alternative for patients with Glanzmann thrombasthenia with anti-platelet antibodies. We describe a case of Glanzmann thrombasthenia with alloantibodies to platelet Gp IIb/IIIa complex who underwent a successful pyelolithotomy operation under the coverage of recombinant activated factor VIIa and platelet transfusions.
Devecioğlu
Omer
O
Division of Hematology/Oncology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Unüvar
Ayşegül
A
Anak
Sema
S
Bilge
Ilmay
I
Ander
Haluk
H
Ziylan
Orhan
O
D002675:Child, Preschool; D015942:Factor VIIa / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017713:Platelet Transfusion; D013915:Thrombasthenia / Q000601:surgery / Q000628:therapy*
D015942:Factor VIIa